Thrombolytic Therapy with Intravenous Recombinant Tissue-type Plasminogen Activator for Acute Ischemic Stroke Patients with Atrial Fibrillation
YU Yong-fei;JIA Fu-min;WEI Heng;ZHANG Li;RUAN Qing-yuan;SONG Lin;YIN Hong-xiang;ZHOU Rui;XU Kang;Department of Neurology,Hubei Xinhua Hospital;
Objective: To investigate the safety and efficacy of thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator(rt-PA) in acute ischemic stroke of patients with or without atrial fibrillation(AF). Methods: Consecutive acute ischemic stroke patients(n=61) treated with intravenous rt-PA within 4.5 h after stroke onset were studied. The patients were divided into groups AF(n=22) and Non-AF(n=39). The clinical characteristics of the two groups were compared. NIHSS and mRS were used to assess the efficacy and safety before thrombolysis and 2 h, 24 h, 7 d, 90 d respectively after thrombolysis. Results: The percentage of males and the median time for the administration of rt-PA were lower in the AF group then those in the Non-AF group(P0.05). The prime SBP was higher in the AF group than that in the Non-AF group. There were no significant differences in the NIHSS at 2 h, 24 h, and 7 d, the efficacy at 7 d, and the mRS at 90 d after thrombolysis between the two groups. Conclusion: There were no significant differences in the safety and efficacy of thrombolytic therapy with rt-PA in treating acute ischemic stroke of patients with or without AF.